Conditions

GLP-1 and Bone Health: What to Monitor During Weight Loss

GLP-1 Companion · 9 min read

One of the more underappreciated considerations in GLP-1 therapy is the effect of substantial weight loss on bone health. Bone mineral density (BMD) is influenced by mechanical loading — the physical stress that weight and exercise place on the skeleton. When body weight decreases significantly, mechanical loading is reduced, and BMD can decline. For patients undergoing major weight loss with medications like semaglutide or tirzepatide, understanding this risk and mitigating it proactively is important, particularly for postmenopausal women and older adults.

How Weight Loss Affects Bone Mineral Density

The relationship between weight and bone health is complex but well-established. Adipose tissue produces estrogens that contribute to bone formation, particularly in postmenopausal women. Mechanical load from body weight stimulates osteoblast activity and bone remodeling. When weight decreases rapidly, both of these protective effects are reduced. Research consistently shows that intentional weight loss — whether through diet, bariatric surgery, or medication — is associated with bone density loss of approximately 1-2% per year of active weight loss at clinically relevant sites including the hip and lumbar spine.

GLP-1 Receptor Agonists and Direct Bone Effects

Beyond the indirect effect of weight loss, GLP-1 receptors are expressed in osteoblasts (bone-forming cells) and may play a direct role in bone metabolism. Preclinical data suggest GLP-1 receptor activation promotes osteoblast differentiation and inhibits osteoclast activity (bone resorption), which could be bone-protective. GIP receptor activation, relevant for tirzepatide, also appears beneficial for bone metabolism in animal studies, with GIP stimulating osteoblast function.

What the STEP Trials Show: Semaglutide Bone Data

The STEP 1 trial evaluated semaglutide 2.4 mg weekly versus placebo in 1,961 adults with obesity over 68 weeks. Semaglutide produced a mean weight loss of 14.9% of body weight. A pre-specified sub-study analyzed bone mineral density changes using DEXA scanning at baseline and week 68. Total hip BMD decreased by 0.79% in the semaglutide group versus 0.27% in the placebo group — a statistically significant difference. Lumbar spine BMD decreased by 0.45% with semaglutide versus a 0.05% increase with placebo.

Crucially, fracture rates were not significantly different between groups: 0.6% in the semaglutide group versus 0.4% in the placebo group, and this difference was not statistically significant. The STEP 5 trial (104-week extension) found similar patterns of modest BMD reduction without significant fracture rate increases. The consensus interpretation is that semaglutide-associated weight loss produces modest, measurable BMD reduction, but fracture risk remains low in the populations studied.

Tirzepatide Bone Data: SURMOUNT Trials

In the SURMOUNT-1 trial, tirzepatide 15 mg produced a mean weight loss of 22.5% of body weight — more than double the STEP 1 result. A bone sub-study assessed DEXA at baseline and week 72. Total hip BMD declined by approximately 1.5% with tirzepatide 15 mg, compared to 0.3% in the placebo group. Despite this larger BMD reduction (proportional to greater weight loss), fracture rates were 0.5% in all tirzepatide dose groups combined versus 0.4% in placebo — again, no significant between-group difference.

The reassuring fracture data likely reflect several factors: the populations studied were mostly middle-aged adults rather than elderly individuals with pre-existing osteoporosis, the study durations were 1-2 years, and active bone-protective co-interventions (calcium, vitamin D, exercise) were not controlled. Long-term fracture data in older, osteoporotic patients are still limited.

Who Is at Highest Risk for Bone Loss During GLP-1 Therapy

• Postmenopausal women: estrogen deficiency already reduces bone protection; additional weight-loss-driven bone loss adds to risk.
• Adults over 65: age-related bone loss is compounded by weight-loss effects.
• Those with pre-existing osteoporosis or osteopenia (T-score below -1.0).
• Patients with vitamin D deficiency or calcium-poor diets.
• Those who are sedentary or lose muscle mass alongside fat mass (sarcopenic obesity).
• Patients with a history of fragility fractures.

Calcium and Vitamin D: Critical Supplements During Weight Loss

Adequate calcium and vitamin D intake are foundational for bone health maintenance during active weight loss. The National Osteoporosis Foundation recommends 1,000 mg calcium daily for adults under 50 and 1,200 mg daily for women over 50 and men over 70, with a target 25-OH vitamin D level of 30-50 ng/mL (75-125 nmol/L). Because GLP-1 medications significantly reduce appetite and food intake, dietary calcium from dairy, fortified foods, and leafy greens may be insufficient, making supplementation important for many patients.

• Calcium carbonate: best absorbed with food; avoid taking more than 500 mg at once as absorption decreases with higher single doses.
• Calcium citrate: absorbed without food, preferred for patients on acid-suppressing medications (PPIs, H2 blockers).
• Vitamin D3 (cholecalciferol): recommended dose 1,000-2,000 IU daily for most adults; higher doses may be needed if starting with deficiency.
• Check 25-OH vitamin D levels at baseline and after 3-6 months of supplementation.

Weight-Bearing Exercise: The Most Powerful Bone Protector

Mechanical loading through weight-bearing and resistance exercise is the most evidence-backed intervention to preserve bone density during weight loss. Studies in bariatric surgery patients show that resistance training (2-3 sessions per week at 60-75% of 1-repetition maximum) can significantly attenuate or fully prevent BMD loss during active weight reduction. The same principle applies to GLP-1-mediated weight loss. Impact activities — walking, jogging, dancing, stair climbing — combined with resistance training provide the most comprehensive bone stimulus.

Monitoring Recommendations

For General GLP-1 Users

Routine DEXA scanning is not recommended for all GLP-1 users. Ensuring adequate calcium and vitamin D intake and engaging in weight-bearing exercise are the primary interventions. A baseline 25-OH vitamin D level and dietary calcium assessment are reasonable starting points.

For Higher-Risk Patients

• Postmenopausal women planning to lose more than 10% of body weight: baseline DEXA, then repeat at 1-2 years.
• Adults over 65 using GLP-1 for more than 1 year: consider DEXA monitoring.
• Patients with pre-existing osteopenia or osteoporosis: coordinate with endocrinology or rheumatology; consider anti-resorptive therapy (bisphosphonates) if fracture risk is elevated.
• Patients who experience a fragility fracture during GLP-1 therapy: full osteoporosis workup warranted.

Bone health on GLP-1 therapy is a manageable concern, not a disqualifying one. The fracture data from major trials are reassuring, but they do not mean we can ignore bone protection — particularly as these medications are used for longer durations and in older populations.

The Bottom Line

GLP-1 medications cause modest but measurable bone density reductions proportional to weight loss magnitude — approximately 1-1.5% at the total hip in the first year of active weight loss. Despite this, fracture rates in STEP and SURMOUNT trials were not significantly elevated compared to placebo. The key protective interventions are adequate calcium and vitamin D intake, consistent resistance and weight-bearing exercise, and DEXA monitoring for those at elevated baseline risk.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.